Dynamic Biotechnology & Genome Invesco ETF (PBE)

$66.25 1.82 (2.67%)

20:00 EST PBE Stock Quote Delayed 30 Minutes

3 of the Best Biotech ETFs on the Market

By Todd Shriber, InvestorPlace Contributor Jan 2, 2020

The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, is up 16.65% since Oct. 1, pushing its year-to-date gain to 26.57% as of Dec. 20. That after months of investors pulling money from actively managed biotech funds, but that situation is starting to correct as well as data out this month indicate investors are warming to biotech assets again.

7 Biotech ETFs That Should Remain Healthy

7 of the Best Biotech ETFs

7 Biotech ETFs to Consider for 2019

More Articles

Volume:

Previous Close -

Market Cap 2.59M

PE Ratio -

EPS -

Volume (Avg. Vol.) 14,249

Day's Range 65.67 - 67.49

52-Week Range 64.34 - 84.86

Dividend & Yield 0.00 (0.00%)

PBE Stock Predictions, Articles, and Dynamic Biotechnology & Genome Invesco ETF News

From InvestorPlace
From the Web

7 Benchmark-Clobbering ETFs to Buy

By Todd Shriber, InvestorPlace Contributor Sep 17, 2018

Finding the best ETFs to buy can be trying, particularly with the universe of smart beta funds rapidly expanding. These funds, however, beat even their benchmarks.

5 Biotech ETFs for Outsized Gains

By Todd Shriber, InvestorPlace Contributor Apr 25, 2018

Data support the notion that biotechnology stocks offer outperformance potential over diversified healthcare benchmarks. And these 5 biotech ETFs are a great to play the space.

Is Now the Time to Buy Into These 5 Biotech ETFs?

By Zacks Investment Research Mar 14, 2017

After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out

3 Biotech ETFs for Decades of Big Returns

By Aaron Levitt, InvestorPlace Contributor Nov 15, 2016

It doesn't matter who is in charge; biotech stocks will always be major growth engines. Here are three of the best biotech ETFs to buy.

4 Frightful ETFs of This Year (VXX, TAPR, KWT, BBC)

By Zacks Investment Research Oct 28, 2016

Let's take a look Inside four heavily losing ETFs in the year-to-date frame.

3 Unheralded Biotech ETFs to Buy Now

By Todd Shriber, InvestorPlace Contributor Jun 29, 2015

Want to join biotech stocks on the industry's seemingly never-ending run higher? Consider these lesser-known biotech ETFs.

A Comprehensive Guide To Genomic ETFs

From Talk Markets Jul 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.

5 Top ETFs With Exposure To Biogen

From Talk Markets Jun 7, 2021

Here is a look at five ETFs with large exposure to Biogen shares.

5 Top ETFs With Exposure To Biogen

From Benzinga Jun 7, 2021

For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...

3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More

From Talk Markets May 30, 2021

Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more than 45% in the near term.

3 Biotech Stocks Wall Street Predicts Will Rally By 45% or More

From StockNews.com May 28, 2021

The biotech industry saw solid growth last year driven by the demand for therapies to combat COVID-19. But advances in technology helped biotech companies deliver impressive drug candidates for treating other serious ailments too. Consequently, Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more than 45% in the near term. So, let’s evaluate these companies more closely.

ETFs in Focus on Bayer's Bet on Gene Therapy

From Talk Markets Oct 30, 2020

Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon.